Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.

摘要: Compelling experimental and clinical evidence suggests that epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of a variety human cancers; thus, providing strong rationale for development antagonists as effective specific therapeutic strategies treatment EGFR-expressing cancers. Monoclonal antibodies (mAb), owing to their high specificity towards given target, represent unique class novel cancer therapeutics. A number anti-EGFR mAb are currently being developed our clinic, including two have been approved by United States Food Drug Administration refractory metastatic colorectal (mCRC) squamous cell carcinomas head neck (SCCHN). Cetuximab (Erbitux, IMC-C225), IgG1 mAb, has demonstrated significant antitumor activity, both single agent combination with chemotherapeutics radiation, patients mCRC SCCHN, respectively. Panitumumab (Vectibix), IgG2 mCRC. These via blocking ligand/receptor interactions, exert biological activity multiple mechanisms, inhibition cycle progression, potentiation apoptosis, DNA repair, angiogenesis, tumor invasion metastasis and, potentially, induction immunological effector mechanisms. Anti-EGFR good safety profiles potent anticancer clinic may prove be efficacious agents malignancies.